Franklin Genomic Advancements ETF closed at $44.40 on Sep 28, up 0.23% — matching its 52-week closing high. Volume of 24.1K shares was 25.33× its 20-day average (well above normal).
Split-adjusted performance: +2.0% over one month, +42.1% over six months, +48.8% over one year.
In the quarter ended Dec 31, 2019, revenue was $170.75M, up 7.8% from a year earlier, with a net margin of 4.6%.
Short interest was 2.1K shares at the Sep 15 settlement, down 12.8% from the prior report (2.0 days to cover).
No recent articles focused on Franklin Genomic Advancements ETF.
Quick answers
What is HELX's market cap?
$33.30M, based on the Sep 28 close of $44.40.
What is HELX's P/E ratio?
0.6× trailing-twelve-month earnings of $57.32M.
Does Franklin Genomic Advancements ETF pay a dividend?
Yes. The latest regular dividend was $0.1433 per share (ex-date Dec 30), an annualised yield of 0.32%.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology